NEW DELHI :
Pfizer Inc. has provided to provide its vaccine to the Indian authorities at a “not-for-profit” worth as a part of its technique to offer distinct costs for the vaccine based mostly on the financial profile of the nation.
“For India, Pfizer has provided a not-for-profit worth for its vaccine for the federal government immunization programme. We proceed to be in discussions with the federal government and stay dedicated to creating our vaccine out there for deployment in India’s immunization programme,” a Pfizer spokesperson stated in a press release on Thursday.
The assertion adopted sure media experiences speculating in regards to the worth of the vaccine in India.
The US agency stated it has adopted variable pricing as a part of its technique to offer vaccines solely to the federal government for its covid-19 immunization programme.
“This is able to be our method in India as effectively. Additional, in all our agreements, Pfizer has adopted a definite pricing construction for prime, center, and low/lower-middle-income international locations, per our dedication to work in the direction of equitable and inexpensive entry for our covid vaccine for individuals all over the world,” the corporate stated.
The corporate spokesperson was not instantly out there to provide particulars on what worth it has provided the federal government.
Within the US, it’s charging $19.5 per dose from the federal government to provide the vaccine, by means of which it expects to make some revenue regardless of chief government officer Albert Bourla calling it “pandemic pricing”. Within the European Union, Pfizer has considerably raised costs over the previous few months from €12 to €15.5 after which €19.5 ($23) per dose for orders in 2022-23.
Pfizer has forecast $15 billion in further gross sales from the vaccine alone in 2021, with its total revenue estimated at $4 billion, in line with varied experiences.